Finerenone demonstrated consistent efficacy and safety in Black and non-Black patients with type 2 diabetes and chronic kidney disease.
RCT
Yes
Does finerenone improve cardiorenal outcomes consistently in Black patients with type 2 diabetes and chronic kidney disease?
Finerenone demonstrates consistent cardiorenal benefits and safety in both Black and non-Black patients with type 2 diabetes and chronic kidney disease.
p-value: p=0.001
Rationale composite of kidney failure, sustained ≥57% estimated glomerular filtration rate (eGFR) decline from baseline maintained for ≥4 weeks, or renal death. Results: 0.001], respectively). Safety outcomes were similar between subgroups. Limitations: Small number of Black patients; analysis was not originally powered to determine an interaction effect based on Black race. Conclusions: The efficacy and safety of finerenone appears consistent in Black and non-Black patients with CKD and T2D. Funding: Bayer AG. Trial Registration: ClinicalTrials.gov NCT02540993, NCT02545049. Plain-Language Summary: Diabetes is a major cause of chronic kidney disease (CKD), affecting more Black adults than White adults. Most adults with CKD ultimately die from heart and vascular complications (eg, heart attack and stroke) rather than kidney failure. This analysis of 2 recent trials shows that the drug finerenone was beneficial for patients with diabetes and CKD. Along with reducing kidney function decline and protein in the urine, it also decreased heart and vascular issues and lowered blood pressure in both Black and non-Black adults with diabetes and CKD. These findings have promising implications for slowing the progression of CKD and protecting against cardiovascular problems in diverse populations.
Flack et al. (Thu,) conducted a rct in Type 2 diabetes and chronic kidney disease. Finerenone vs. Placebo was evaluated on Composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure; composite of kidney failure, sustained ≥57% eGFR decline, or renal death (p=0.001). Finerenone demonstrated consistent efficacy and safety in Black and non-Black patients with type 2 diabetes and chronic kidney disease.